Insights - Amarin Corporation (AMRN) reported quarterly results on Friday morning, $0.02 ahead of consensus EPS but below expectations on the top-line with a $1.6M miss. Cost-cutting … Continue Reading
Insights - Sarepta Therapeutics (SRPT) last Thursday morning released its fourth quarter and full-year 2013 financial results and hosted a conference call for investors. SRPT’s 2014 outlook … Continue Reading
Insights - Bristol-Myers Squibb (BMY) on Monday announced that the U.S. FDA granted its investigational DCV Dual Regimen (daclatasvir and asunaprevir) Breakthrough Therapy Designation as a combination therapy … Continue Reading
Insights - On the heels of dropping its bid to acquire troubled Transcept Pharmaceuticals (TSPT), Retrophin, Inc. (RTRX) announced its newest clinical development candidate on Wednesday: RE-034 … Continue Reading
Insights - Alcobra Ltd. (ADHD) announced on Monday that its proprietary non-stimulant drug candidate, Metadoxine ER (MG01CI), delivered statistically positive results in a phase 2b clinical trial in adults with … Continue Reading
You're all done! We've sent you a confirmation email that includes a verification link. To access the page you're interested in, check your email inbox(including spam folder) and click the verification link.